Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 10
Submit an article Journal homepage
76
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

It’s all about the CD3+ T-cells: how circulating immune cell subset analyses can predict early relapse in Hodgkin lymphoma

Jonathan MoreiraRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; ;Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Correspondence[email protected]
,
Leonidas C. PlataniasRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; ;Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; ;Department of Medicine, Jesse Brown VA Medical Center, Chicago, IL, USA
&
Kehinde U. A. AdekolaRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; ;Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA;
Pages 2345-2347 | Received 26 Jun 2019, Accepted 27 Jun 2019, Published online: 27 Aug 2019

References

  • Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2015. April 2018 ed. Bethesda (MD): National Cancer Institute; 2018.
  • Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363:640–652.
  • Straus DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018;132:1013–1021.
  • Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet (London, England). 2012;379:1791–1799.
  • Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378:331–344.
  • Carde P, Karrasch M, Fortpied C, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score >/ = 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016;34:2028–2036.
  • Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12:1065–1072.
  • Hahn T, McCarthy PL, Carreras J, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013;19:1740–1744.
  • Chan FC, Mottok A, Gerrie AS, et al. Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma. J Clin Oncol. 2017;35:3722–3733.
  • Batorov EP, Tikhonova M, Kryuchkova I, et al. Increased circulating CD3+ T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2019;60:2488–2497.
  • Ngoenkam J, Schamel WW, Pongcharoen S. Selected signalling proteins recruited to the T-cell receptor-CD3 complex. Immunology. 2018;153:42–50.
  • Vardhana S, Younes A. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica. 2016;101:794–802.
  • Zhang YP, Zhang R, Zhu HY, et al. Circulating low absolute CD4+ T cell counts may predict poor prognosis in extranodal NK/T-cell lymphoma patients treating with pegaspargase-based chemotherapy. Cancer Res Treat. 2019;51:368–377.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.